Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Jan 15:10:9.
doi: 10.1186/1471-2334-10-9.

Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

Michael Steiner  1 , Gunasekaran Ramakrishnan, Britta Gartner, Olivier Van Der Meeren, Jeanne-Marie Jacquet, Volker Schuster
Affiliations
Multicenter Study

Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

Michael Steiner et al. BMC Infect Dis. .

Abstract

Background: Few studies have assessed long term persisting immunity against hepatitis B virus (HBV) in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs). We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

Methods: Immune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine.

Results: At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations >or= 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8%) achieved post-challenge anti-HBs concentrations >or= 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0%) of children with initially undetectable antibodies (<3.3 mIU/mL). All but 4 of 42 subjects (90.5%) with anti-HBs antibodies <10 mIU/mL prior to the challenge dose, achieved seroprotective levels afterwards. A 4-fold rise in antibody concentration after the challenge dose was observed in 259/264 (98.1%) of initially seropositive subjects. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels. No serious adverse events were reported during the study.

Conclusion: The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines.

Trial registration: http://www.clinicaltrials.gov 106789 NCT00411697.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).
See this image and copyright information in PMC

References

    1. World Health Organization. Hepatitis B vaccines WHO position paper. WER. 2004;79:255–263. - PubMed
    1. World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull WHO. 1988;66:443–455. - PMC - PubMed
    1. Lawrence MH, Goldstein MA. Hepatitis B immunization in adolescents. J Adolesc Health. 1995;17:234–243. doi: 10.1016/1054-139X(95)00165-O. - DOI - PubMed
    1. Centers for Disease Control and Prevention. Hepatitis B Virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR. 1991;40(RR-13):1–19. - PubMed
    1. Brabin L, Greenberg DP, Hessel L, Hyer R, Ivanoff B, Van Damme P. Current issues in adolescent immunization. Vaccine. 2008;26:4120–34. doi: 10.1016/j.vaccine.2008.04.055. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data